Belgium· BE-AMP-SAM663668-00
Hympavzi 150 mg
A marstacimab product containing marstacimab, registered in Belgium by Pfizer Europe MA. The same ATC class is registered in 11 of our 19 countries.
Checked against FAMHP / AFMPS (Belgium) on
Informational only — not a medical device.
Where it is registered
Marstacimab is registered in 11 of 19 countries.
Countries holding a registration under ATC B02BX11 (marstacimab), each read from that country’s own register.
- This record: Belgium, from FAMHP / AFMPS (Belgium)
- 7 of them publish a price we can compare per daily dose
Marstacimab · ATC B02BX11
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
FAMHP / AFMPS (Belgium)- Active substance
- Marstacimab
- Manufacturer
- Pfizer Europe MA
- Country
- Belgium (BE)
- ATC code
- B02BX11
- ATC class
- Marstacimab
- Defined daily dose
- 21 mg, P
- Reimbursed
- Not published by this register
- Source register
- FAMHP / AFMPS (Belgium)
- Last checked
- September 26, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Marstacimab in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaHYMPAVZIPfizer Europe MA EEIG, Bruxelles
- IcelandHympavziPfizer Europe MA EEIG*
- SwedenHympavzi 150 mg Injektionsvätska, lösning i förfylld injektionspennaPfizer Europe MA EEIG
- NorwayHympavziPfizer Europe MA EEIG
- United KingdomHympavzi 150mg/1ml solution for injection pre-filled pensPfizer Ltd
- SpainHYMPAVZI 150 MG SOLUCION INYECTABLE EN PLUMA PRECARGADAPfizer Europe Ma Eeig
- United StatesHYMPAVZIPfizer Laboratories Div Pfizer Inc
- IrelandHympavzi 150 mg solution for injection in pre-filled penPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Hympavzi
- Liechtenstein · Hympavzi
- Norway · Hympavzi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FAMHP / AFMPS (Belgium). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/668b7358-6a4a-458b-802a-a35748b2fa8c GET /v1/drugs/668b7358-6a4a-458b-802a-a35748b2fa8c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Solution for injection in pre-filled syringe",
"source": "afmps",
"status": "AUTHORIZED",
"name_en": "Hympavzi 150 mg",
"name_fr": "Hympavzi 150 mg",
"name_nl": "Hympavzi 150 mg",
"amp_code": "SAM663668-00",
"strengths": [
"150.0000",
"150.0000",
"0.2000"
],
"pack_count": 1,
"substances": [
"Marstacimab",
"Disodium Edetate",
"Sucrose",
"Polysorbate 80"
],
"medicine_type": "ALLOPATHIC",
"atc_description": "Marstacimab",
"authorisation_numbers": [
"EU/1/24/1874/001"
]
}See everything about marstacimab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.